Leigh M Howard1, Johannes B Goll2, Travis L Jensen2, Kristen L Hoek3, Nripesh Prasad4, Casey E Gelber2, Shawn E Levy4, Sebastian Joyce3,5, Andrew J Link3,6,7, C Buddy Creech1, Kathryn M Edwards1. 1. Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee. 2. The Emmes Corporation, Rockville, Maryland. 3. Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee. 4. HudsonAlpha Institute for Biotechnology, Huntsville, Alabama. 5. Veterans Administration Tennessee Valley Healthcare System, Nashville. 6. Department of Chemistry, Vanderbilt University, Nashville, Tennessee. 7. Department of Biochemistry, Vanderbilt University, Nashville, Tennessee.
Abstract
BACKGROUND: Adjuvant System 03 (AS03) markedly enhances responses to influenza A/H5N1 vaccines, but the mechanisms of this enhancement are incompletely understood. METHODS: Using ribonucleic acid sequencing on peripheral blood mononuclear cells (PBMCs) from AS03-adjuvanted and unadjuvanted inactivated H5N1 vaccine recipients, we identified differentially expressed genes, enriched pathways, and genes that correlated with serologic responses. We compared bulk PBMC findings with our previously published assessments of flow-sorted immune cell types. RESULTS:AS03-adjuvanted vaccine induced the strongest differential signals on day 1 postvaccination, activating multiple innate immune pathways including interferon and JAK-STAT signaling, Fcγ receptor (FcγR)-mediated phagocytosis, and antigen processing and presentation. Changes in signal transduction and immunoglobulin genes predicted peak hemagglutinin inhibition (HAI) titers. Compared with individual immune cell types, activated PBMC genes and pathways were most similar to innate immune cells. However, several pathways were unique to PBMCs, and several pathways identified in individual cell types were absent in PBMCs. CONCLUSIONS: Transcriptomic analysis of PBMCs after AS03-adjuvanted H5N1 vaccination revealed early activation of innate immune signaling, including a 5- to 8-fold upregulation of FcγR1A/1B/1C genes. Several early gene responses were correlated with HAI titer, indicating links with the adaptive immune response. Although PBMCs and cell-specific results shared key innate immune signals, unique signals were identified by both approaches.
RCT Entities:
BACKGROUND: Adjuvant System 03 (AS03) markedly enhances responses to influenza A/H5N1 vaccines, but the mechanisms of this enhancement are incompletely understood. METHODS: Using ribonucleic acid sequencing on peripheral blood mononuclear cells (PBMCs) from AS03-adjuvanted and unadjuvanted inactivated H5N1 vaccine recipients, we identified differentially expressed genes, enriched pathways, and genes that correlated with serologic responses. We compared bulk PBMC findings with our previously published assessments of flow-sorted immune cell types. RESULTS: AS03-adjuvanted vaccine induced the strongest differential signals on day 1 postvaccination, activating multiple innate immune pathways including interferon and JAK-STAT signaling, Fcγ receptor (FcγR)-mediated phagocytosis, and antigen processing and presentation. Changes in signal transduction and immunoglobulin genes predicted peak hemagglutinin inhibition (HAI) titers. Compared with individual immune cell types, activated PBMC genes and pathways were most similar to innate immune cells. However, several pathways were unique to PBMCs, and several pathways identified in individual cell types were absent in PBMCs. CONCLUSIONS: Transcriptomic analysis of PBMCs after AS03-adjuvanted H5N1 vaccination revealed early activation of innate immune signaling, including a 5- to 8-fold upregulation of FcγR1A/1B/1C genes. Several early gene responses were correlated with HAI titer, indicating links with the adaptive immune response. Although PBMCs and cell-specific results shared key innate immune signals, unique signals were identified by both approaches.
Authors: Joanne M Langley; Louise Frenette; Linda Ferguson; Dennis Riff; Eric Sheldon; George Risi; Casey Johnson; Ping Li; Richard Kenney; Bruce Innis; Louis Fries Journal: J Infect Dis Date: 2010-06-01 Impact factor: 5.226
Authors: Colin A Russell; Judith M Fonville; André E X Brown; David F Burke; David L Smith; Sarah L James; Sander Herfst; Sander van Boheemen; Martin Linster; Eefje J Schrauwen; Leah Katzelnick; Ana Mosterín; Thijs Kuiken; Eileen Maher; Gabriele Neumann; Albert D M E Osterhaus; Yoshihiro Kawaoka; Ron A M Fouchier; Derek J Smith Journal: Science Date: 2012-06-22 Impact factor: 47.728
Authors: Helder I Nakaya; Jens Wrammert; Eva K Lee; Luigi Racioppi; Stephanie Marie-Kunze; W Nicholas Haining; Anthony R Means; Sudhir P Kasturi; Nooruddin Khan; Gui-Mei Li; Megan McCausland; Vibhu Kanchan; Kenneth E Kokko; Shuzhao Li; Rivka Elbein; Aneesh K Mehta; Alan Aderem; Kanta Subbarao; Rafi Ahmed; Bali Pulendran Journal: Nat Immunol Date: 2011-07-10 Impact factor: 25.606
Authors: G Joshi-Tope; M Gillespie; I Vastrik; P D'Eustachio; E Schmidt; B de Bono; B Jassal; G R Gopinath; G R Wu; L Matthews; S Lewis; E Birney; L Stein Journal: Nucleic Acids Res Date: 2005-01-01 Impact factor: 16.971
Authors: Ali H Ellebedy; Raffael Nachbagauer; Katherine J L Jackson; Ya-Nan Dai; Julianna Han; Wafaa B Alsoussi; Carl W Davis; Daniel Stadlbauer; Nadine Rouphael; Veronika Chromikova; Megan McCausland; Cathy Y Chang; Mario Cortese; Mary Bower; Chakravarthy Chennareddy; Aaron J Schmitz; Veronika I Zarnitsyna; Lilin Lai; Arvind Rajabhathor; Cheyann Kazemian; Rustom Antia; Mark J Mulligan; Andrew B Ward; Daved H Fremont; Scott D Boyd; Bali Pulendran; Florian Krammer; Rafi Ahmed Journal: Proc Natl Acad Sci U S A Date: 2020-07-13 Impact factor: 12.779
Authors: Muktha S Natrajan; Nadine Rouphael; Lilin Lai; Dmitri Kazmin; Travis L Jensen; David S Weiss; Chris Ibegbu; Marcelo B Sztein; William F Hooper; Heather Hill; Evan J Anderson; Robert Johnson; Patrick Sanz; Bali Pulendran; Johannes B Goll; Mark J Mulligan Journal: Vaccines (Basel) Date: 2019-12-24
Authors: Johannes B Goll; Shuzhao Li; James L Edwards; Steven E Bosinger; Travis L Jensen; Yating Wang; William F Hooper; Casey E Gelber; Katherine L Sanders; Evan J Anderson; Nadine Rouphael; Muktha S Natrajan; Robert A Johnson; Patrick Sanz; Daniel Hoft; Mark J Mulligan Journal: Vaccines (Basel) Date: 2020-07-24
Authors: Stéphane Pillet; Prabhu S Arunachalam; Guadalupe Andreani; Nadia Golden; Jane Fontenot; Pyone Pyone Aye; Katharina Röltgen; Gabrielle Lehmicke; Philipe Gobeil; Charlotte Dubé; Sonia Trépanier; Nathalie Charland; Marc-André D'Aoust; Kasi Russell-Lodrigue; Christopher Monjure; Robert V Blair; Scott D Boyd; Rudolf P Bohm; Jay Rappaport; François Villinger; Nathalie Landry; Bali Pulendran; Brian J Ward Journal: Cell Mol Immunol Date: 2022-01-05 Impact factor: 22.096
Authors: Derek T O'Hagan; Robbert van der Most; Rushit N Lodaya; Margherita Coccia; Giuseppe Lofano Journal: NPJ Vaccines Date: 2021-12-21 Impact factor: 7.344